Introduction

Ibrutinib is a Bruton Tyrosine Kinase (BTK) inhibitor approved in 2014 to treat Chronic Lymphocytic Leukemia (CLL). Since its inception, it has shown considerable improvements in CLL’s progression-free survival and overall survival in addition to improvement in hematologic variables (Burger et al., 2015). While it has garnered acclaim for its usefulness in lymphoproliferative disease, it has also gathered notoriety due to an alarming amount of reports of Invasive Fungal Infections (IFIs) after starting ibrutinib. Chamilos et al. (2018) reported 41 cases of IFI including cryptococcosis, invasive aspergillosis, and mucormycosis in patients on ibrutinib therapy (Chamilos et al., 2018). It has been reported that the median time from the start of ibrutinib treatment until the first symptoms of IFI was 45.5 days (range 1-540 days) (Ruchlemer et al., 2019). Early occurrences of IFI are thought to be due to the inactivation of monocytes allowing increased susceptibility in patients who were previously colonized to these typically non-pathogenic fungi (Grommes and Younes, 2017). Cryptococcosis, specifically Cryptococcus neoformans, has historically been an ailment in immunocompromised hosts. Cryptococci reside in diverse ecological niches and are typically isolated to soil microorganism interaction with vertebrae possibly aiding in its spread (May et al., 2016). As the portal of entry is the lungs, pneumonia is the presenting diagnosis, but it can manifest elsewhere in the body. In 2013, only 89 cases of cryptococcosis were reported to involve bones and joints. Characteristic symptoms of skeletal cryptococcosis are pain and swelling at the site. Amongst implicated bones, the majority involve the vertebrae, skull, and femur. The ribs and ilium comprised 8.1 and 4.9% of affected sites, respectively (Zhou et al., 2015). This is different from previously reported most common sites as the pelvis and rib in 1977 (Chleboun and Nade, 1977). One patient had CLL; he presented with a lump on his scalp and was found to have a cryptococcal skull granuloma (Galloway and Schochet, 1981). A similar case of disseminated cryptococcosis in a patient with CLL on ibrutinib did not have any skeletal involvement (Okamoto et al., 2016). To the best of our knowledge, this case is the first reported case of disseminated cryptococcosis with skeletal and pulmonary involvement in an individual with CLL who was on ibrutinib therapy.

Objective

While guidelines for cryptococcal meningitis have been outlined in detail by the infectious diseases society of America, optimal therapy for skeletal cryptococcosis has yet to be established. Below, we present a case of skeletal cryptococcosis and a possible antifungal regimen.

Case Report

A 77-year-old female with CLL on ibrutinib presented with a one-week history of dyspnea, fatigue, and fevers and a reported Tmax of 105.5°F (40.8°C). She was diagnosed with pneumonia and given a seven-day course of levofloxacin. Her fevers reoccurred along with new orthopnea and worsening lower extremity edema. She

American Journal of Infectious Diseases

Case Report

Disseminated Cryptococcal Disease with Skeletal and Pulmonary Involvement

1Nikko Rowe Asuncion Tabliago, 2Paula McKenzie, 3Caroline Dillon and 4Amelia Morgan

1Department of Internal Medicine, Geisinger Medical Center, USA
2Department of Infectious Diseases, Geisinger Medical Center, USA
3Department of Pharmacy, Geisinger Medical Center, USA
4Department of Internal Medicine-Pediatrics, Geisinger Medical Center, USA

Abstract: Cryptococcus neoformans is an encapsulated yeast that typically causes illness in immunocompromised hosts. Manifestations of the disease include pulmonary, Central Nervous System (CNS), and rare skeletal involvement. Optimal antifungal therapy for skeletal involvement has yet to be established. Here we present a potential antifungal regimen for disseminated cryptococcal disease with skeletal and pulmonary involvement in a patient with Chronic Lymphocytic Leukemia (CLL) on ibrutinib therapy.

Keywords: Cryptococcosis, Osteomyelitis, Fluconazole, Disseminated
was tachycardic, tachypneic, and hypoxic requiring two liters of oxygen. Initial laboratory studies showed a white blood cell count of 19,520 cells/μL, hemoglobin 7.6 g/dL, platelets 84,000 cells/μL and elevated transaminases. She was started on ceftriaxone and azithromycin but remained febrile. Ibrutinib was discontinued at this time as well due to her acute infection. Diuresis subjectively improved her orthopnea, dyspnea, and peripheral edema, but her fevers continued to spike up to 102.2°F (39.0°C); antibiotic coverage was broadened to cefepime to provide (SPICE) Serratia, Pseudomonas, indole-positive Proteus, Citrobacter, and Enterobacter organism coverage. Our differential expanded to include evaluation for reactivation of Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), and Cryptococcus gave her immunocompromised status from taking daily ibrutinib. EBV and CMV returned negative. Serum Cryptococcal antigen titer was 1:160. Blood cultures grew Cryptococcus neoformans. A working diagnosis of disseminated cryptococcal infection was established and a lumbar puncture was performed to rule out Central Nervous System (CNS) involvement. Cerebrospinal Fluid (CSF) studies did not show any findings consistent with fungal meningitis and culture growth was ultimately negative. Transthoracic Echocardiogram (TTE) showed a 1.2 × 0.78 cm vegetation with moderate mitral regurgitation. Transesophageal Echocardiogram (TEE) showed that this lesion was more consistent with mitral valve chordae calcification. She received two weeks of induction antifungal therapy with IV amphotericin B and oral flucytosine. At the time of discharge, her oral consolidation regimen consisted of fluconazole 400 mg for eight weeks with short interval follow-up imaging regarding possible cardiac mass. Outpatient cardiac Magnetic Resonance Imaging (MRI) was completed in addition to a Positron Emission Tomography (PET) scan and it was determined the vegetation was likely a myxoma, not fungal endocarditis. Based on the site of the lesion and the overall stability of the patient on the current regimen, the decision was made to not pursue an invasive biopsy of this lesion as it would not have changed the current management. Of particular interest in this imaging was the newly identified active osteolytic lesions (Fig. 1 and 2) scattered throughout her skeleton thought to be concerning for CLL disease progression. The decision was made to biopsy the more accessible 4th rib lesion which ultimately showed small B-cell lymphoma compatible with CLL as well as necrotizing granulomatous inflammation with fungal elements, morphologically compatible with Cryptococcus (Fig. 3). After this result, the regimen was changed to oral fluconazole 800 mg daily and oral flucytosine 1,250 mg twice daily for two weeks for re-induction, then transitioned to fluconazole 400 mg daily for 8-10 weeks and then lifelong fluconazole 200 mg daily.

Discussion

To our knowledge, this case is the first reported case of disseminated cryptococcosis with skeletal and pulmonary involvement in an individual with CLL who was on ibrutinib therapy. It is likely that the Cryptococcus spp. First manifested as pneumonia and then spread via hematogenous dissemination to involve the bony structures. A literature review of disseminated skeletal cryptococcosis showed no significant differences in mortality rates amongst four treatment regimens: Medical...
monotherapy, combined medical therapy, medical monotherapy with surgery, and combined medical therapy with surgery (Zhou et al., 2015); this may be skewed due to the small sample size (n = 40). It is reasonable that the combination of surgery for source control and combined medical therapy would be a plausible regimen to ensure clearance of infection. As our patient potentially had multiple bony sites affected, surgical debridement would be difficult to safely pursue. Fluconazole concentration may only reach 33% in bone (Ashbee et al., 2014). Current recommendations neither support nor refute routine Therapeutic Drug Monitoring (TDM) for fluconazole. There is limited data available on the bone concentrations of flucytosine in humans and animals. Polak (1979) reported that flucytosine concentration reached up to 30% in bone. It is recommended that TDM should be performed in the majority of patients receiving flucytosine with lower target concentrations of >20-40 mg/L (Ashbee et al., 2014).

Conclusion
There is little consensus as to a definitive antifungal regimen. We have presented a potential antifungal regimen for disseminated cryptococcal disease with skeletal and pulmonary involvement. Its efficacy in successfully suppressing this challenging infection will warrant close monitoring.

Acknowledgment
Xiaoyu Tang, MD-Pathology, Geisinger Medical Center, Danville, Pennsylvania, United States of America.

Author’s Contributions
Nikko Rowe Asuncion Tabliago: Manuscript write, literature review and edited.
Paula McKenzie: Manuscript review and edited, supervision of project.
Caroline Dillon: Manuscript review and edited.
Amelia Morgan: Manuscript write and edited.

Ethics
This article is original and contains unpublished material. The authors declare no ethical issues. Informed consent was acquired from the patient.

References


